Lo P K, Fink D W, Williams J B, Blodinger J
Vet Res Commun. 1985 Sep;9(4):251-68. doi: 10.1007/BF02215150.
Studies are reported which describe the effects of formulation, animal species, and route of administration on the pharmacokinetics of ivermectin. Biological half-life t1/2 increases in the order: swine (0.5 day) less than dogs (1.8 day) less than cattle approximately equal to sheep (2.8 day). Formulation modifications, based upon the solubility properties of the drug, have been directed towards the development of a nonaqueous injectable formulation for cattle and an aqueous vehicle for horses. Bioavailability following subcutaneous injection in cattle can be regulated by control of injection solvent composition: a vehicle composed of a mixed aqueous-organic solvent exhibits pharmacokinetic properties (i.e., Cp, t1/2, AUC, and F) intermediate between those furnished by an aqueous formulation and via a purely nonaqueous solvent. The longer apparent biological half-life from this latter vehicle (t1/2 = 8.3 days) confirms that a slow absorption process dominates the pharmacokinetics in the nonaqueous injectable product to produce an effective controlled-release formulation. These bioavailability results illustrate the increase in the concentration of an organic solvent and a concomitant decrease in surfactant concentration in a micellar aqueous system for prolonged drug delivery via injection.
有研究报道了制剂、动物种类和给药途径对伊维菌素药代动力学的影响。生物半衰期t1/2按以下顺序增加:猪(0.5天)<犬(1.8天)<牛≈羊(2.8天)。基于药物的溶解性,制剂改进旨在开发一种用于牛的非水性注射剂和一种用于马的水性载体。牛皮下注射后的生物利用度可通过控制注射溶剂组成来调节:由混合水性-有机溶剂组成的载体表现出介于水性制剂和纯非水性溶剂所提供的药代动力学性质(即血药浓度(Cp)、半衰期(t1/2)、药时曲线下面积(AUC)和生物利用度(F))之间的性质。后一种载体的表观生物半衰期较长(t1/2 = 8.3天),这证实了缓慢吸收过程主导了非水性注射产品的药代动力学,从而产生了一种有效的控释制剂。这些生物利用度结果表明,在胶束水性体系中,有机溶剂浓度增加,表面活性剂浓度随之降低,可通过注射实现药物的长效递送。